Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer.

Barnes J, Kennedy WR, Fischer-Valuck BW, Baumann BC, Michalski JM, Gay HA.

J Contemp Brachytherapy. 2019 Aug;11(4):320-328. doi: 10.5114/jcb.2019.86974. Epub 2019 Aug 29.

2.

Favorable long-term toxicity for salvage low-dose rate prostate brachytherapy for recurrent prostate cancer after external beam radiotherapy from a phase II prospective trial (NRG Oncology/RTOG 0526).

Brenneman RJ, Soffen E, Gay HA, Orio PF 3rd, Christodouleas JP, Baumann JC, Baumann BC.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S265-S270. doi: 10.21037/tau.2019.03.14. No abstract available.

3.

Review of hypo-fractionated radiotherapy for localized muscle invasive bladder cancer.

Amestoy F, Roubaud G, Antoine M, Fonteyne V, Baumann BC, Christodouleas J, Roupret M, Azria D, Zilli T, Hennequin C, Xylinas E, Sargos P; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology.

Crit Rev Oncol Hematol. 2019 Oct;142:76-85. doi: 10.1016/j.critrevonc.2019.06.010. Epub 2019 Jul 16. Review.

PMID:
31377435
4.

Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer.

Fischer-Valuck BW, Michalski JM, Mitra N, Christodouleas JP, DeWees TA, Kim E, Smith ZL, Andriole GL, Arora V, Bullock A, Carmona R, Figenshau RS, Grubb RL, Guzzo TJ, Knoche EM, Malkowicz SB, Mamtani R, Pachynski RK, Roth BJ, Zaghloul MS, Gay HA, Baumann BC.

Cancer Med. 2019 Jul;8(8):3698-3709. doi: 10.1002/cam4.2102. Epub 2019 May 22.

5.

A prospective clinical trial of proton therapy for chordoma and chondrosarcoma: Feasibility assessment.

Baumann BC, Lustig RA, Mazzoni S, Grady SM, O'Malley BW, Lee JYK, Newman JG, Schuster JM, Both S, Lin A, Dorsey JF, Alonso-Basanta M.

J Surg Oncol. 2019 Aug;120(2):200-205. doi: 10.1002/jso.25502. Epub 2019 May 20.

PMID:
31111502
6.

A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database.

Fischer-Valuck BW, Michalski JM, Contreras JA, Brenneman R, Christodouleas JP, Abraham CD, Kim EH, Arora VK, Bullock AD, Carmona R, Figenshau RS, Grubb R 3rd, Knoche EM, Pachynski RK, Picus J, Roth BJ, Sargos P, Andriole GL, Gay HA, Baumann BC.

Clin Transl Radiat Oncol. 2018 Dec 12;15:38-41. doi: 10.1016/j.ctro.2018.12.001. eCollection 2019 Feb.

7.

Assessing the Validity of Clinician Advice That Patients Avoid Use of Topical Agents Before Daily Radiotherapy Treatments.

Baumann BC, Verginadis II, Zeng C, Bell B, Koduri S, Vachani C, MacArthur KM, Solberg TD, Koumenis C, Metz JM.

JAMA Oncol. 2018 Dec 1;4(12):1742-1748. doi: 10.1001/jamaoncol.2018.4292.

PMID:
30347008
8.

Radiomics-guided therapy for bladder cancer: Using an optimal biomarker approach to determine extent of bladder cancer invasion from t2-weighted magnetic resonance images.

Tong Y, Udupa JK, Wang C, Chen J, Venigalla S, Guzzo TJ, Mamtani R, Baumann BC, Christodouleas JP, Torigian DA.

Adv Radiat Oncol. 2018 May 8;3(3):331-338. doi: 10.1016/j.adro.2018.04.011. eCollection 2018 Jul-Sep.

9.

Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy.

Sargos P, Baumann BC, Eapen L, Christodouleas J, Bahl A, Murthy V, Efstathiou J, Fonteyne V, Ballas L, Zaghloul M, Roubaud G, Orré M, Larré S.

Cancer Treat Rev. 2018 Nov;70:88-97. doi: 10.1016/j.ctrv.2018.07.011. Epub 2018 Jul 21. Review.

PMID:
30125800
10.

Palliative radiation therapy (RT) for prostate cancer patients with bone metastases at diagnosis: A hospital-based analysis of patterns of care, RT fractionation scheme, and overall survival.

Fischer-Valuck BW, Baumann BC, Apicelli A, Rao YJ, Roach M, Daly M, Dans MC, White P, Contreras J, Henke L, Gay H, Michalski JM, Abraham C.

Cancer Med. 2018 Sep;7(9):4240-4250. doi: 10.1002/cam4.1655. Epub 2018 Aug 17.

11.

Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: High Rates of Local Control With Low Toxicity.

Baumann BC, Wei J, Plastaras JP, Lukens JN, Damjanov N, Hoteit M, Hsu C, Levine M, Mondschein J, Nadolski G, Olthoff K, Reiss KA, Rosen M, Siegelman E, Metz JM, Ben-Josef E.

Am J Clin Oncol. 2018 Mar 16. doi: 10.1097/COC.0000000000000435. [Epub ahead of print]

PMID:
29553972
12.

Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.

Zaghloul MS, Christodouleas JP, Smith A, Abdallah A, William H, Khaled HM, Hwang WT, Baumann BC.

JAMA Surg. 2018 Jan 17;153(1):e174591. doi: 10.1001/jamasurg.2017.4591. Epub 2018 Jan 17.

13.

Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder.

Fischer-Valuck BW, Rao YJ, Henke LE, Rudra S, Hui C, Baumann BC, Gay HA, Michalski JM.

Eur Urol Focus. 2018 Dec;4(6):900-906. doi: 10.1016/j.euf.2017.09.001. Epub 2017 Sep 14.

PMID:
28919521
14.

Treatment Patterns and Overall Survival Outcomes of Octogenarians with Muscle Invasive Cancer of the Bladder: An Analysis of the National Cancer Database.

Fischer-Valuck BW, Rao YJ, Rudra S, Przybysz D, Germino E, Samson P, Baumann BC, Gay H, Michalski J.

J Urol. 2018 Feb;199(2):416-423. doi: 10.1016/j.juro.2017.08.086. Epub 2017 Aug 24.

PMID:
28842247
15.

Avoiding antiperspirants during breast radiation therapy: Myth or sound advice?

Baumann BC, Zeng C, Freedman GM, Verginadis II, MacArthur KM, Lin LL, Vachani C, Koumenis C, Solberg TD, Metz JM.

Radiother Oncol. 2017 Aug;124(2):204-207. doi: 10.1016/j.radonc.2017.06.021. Epub 2017 Jul 18.

PMID:
28733055
16.

The Rationale for Post-Operative Radiation in Localized Bladder Cancer.

Baumann BC, Sargos P, Eapen LJ, Efstathiou JA, Choudhury A, Bahl A, Murthy V, Ballas LK, Fonteyne V, Richaud PM, Zaghloul MS, Christodouleas JP.

Bladder Cancer. 2017 Jan 27;3(1):19-30. doi: 10.3233/BLC-160081. Review.

17.

Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.

Baumann BC, Baumann JC, Christodouleas JP, Soffen E.

Brachytherapy. 2017 Mar - Apr;16(2):291-298. doi: 10.1016/j.brachy.2016.12.011. Epub 2017 Jan 27.

PMID:
28139422
18.

In Reply to Leung.

Christodouleas JP, Eapen LJ, Baumann BC.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1128-1129. doi: 10.1016/j.ijrobp.2016.09.001. No abstract available.

PMID:
27869090
19.

Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710.

Ojerholm E, Smith A, Hwang WT, Baumann BC, Tucker KN, Lerner SP, Mamtani R, Boursi B, Christodouleas JP.

Cancer. 2017 Mar 1;123(5):794-801. doi: 10.1002/cncr.30422. Epub 2016 Oct 27.

20.

Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?

Sargos P, Baumann BC, Eapen LJ, Bahl A, Murthy V, Roubaud G, Orré M, Efstathiou JA, Shariat S, Larré S, Richaud P, Christodouleas JP.

Transl Androl Urol. 2016 Oct;5(5):702-710. Review.

21.

Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy.

Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, El-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master V, Mitra AV, Murthy V, Porten SP, Richaud PM, Sargos P, Efstathiou JA, Eapen LJ, Christodouleas JP.

Int J Radiat Oncol Biol Phys. 2016 Sep 1;96(1):78-86. doi: 10.1016/j.ijrobp.2016.04.032. Epub 2016 May 7. Erratum in: Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1129.

22.

Laparoscopic Versus Open Resection for Gastrointestinal Stromal Tumors (GISTs).

MacArthur KM, Baumann BC, Nicholl MB.

J Gastrointest Cancer. 2017 Mar;48(1):20-24. doi: 10.1007/s12029-016-9861-1.

PMID:
27491685
23.

Emotional support animals on commercial flights: a risk to allergic patients.

Baumann BC, MacArthur KM, Baumann JC.

Lancet Respir Med. 2016 Jul;4(7):544-545. doi: 10.1016/S2213-2600(16)30143-6. No abstract available.

PMID:
27396763
24.

Theranostic Application of Mixed Gold and Superparamagnetic Iron Oxide Nanoparticle Micelles in Glioblastoma Multiforme.

Sun L, Joh DY, Al-Zaki A, Stangl M, Murty S, Davis JJ, Baumann BC, Alonso-Basanta M, Kaol GD, Tsourkas A, Dorsey JF.

J Biomed Nanotechnol. 2016 Feb;12(2):347-56.

26.

Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection.

Baumann BC, Nagda SN, Kolker JD, Levin WP, Weber KL, Berman AT, Staddon A, Hartner L, Hahn SM, Glatstein E, Simone CB 2nd.

J Surg Oncol. 2016 Jul;114(1):65-9. doi: 10.1002/jso.24268. Epub 2016 Apr 25.

PMID:
27111504
27.

Adjuvant Radiation for Locally Advanced Bladder Cancer? A Question Worth Asking.

Christodouleas JP, Hwang WT, Baumann BC.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1040-2. doi: 10.1016/j.ijrobp.2016.01.015. Epub 2016 Jan 19. Review. No abstract available.

PMID:
27026310
28.

Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer.

Baumann BC, He J, Hwang WT, Tucker KN, Bekelman JE, Herr HW, Lerner SP, Guzzo TJ, Malkowicz SB, Christodouleas JP.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):703-6. doi: 10.1016/j.ijrobp.2016.01.034. Epub 2016 Jan 23.

29.

Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.

Sohlberg E, Pfefferle A, Andersson S, Baumann BC, Hellström-Lindberg E, Malmberg KJ.

Oncotarget. 2015 Oct 27;6(33):34178-90. doi: 10.18632/oncotarget.6213.

30.

Adjuvant radiation therapy for bladder cancer: a dosimetric comparison of techniques.

Baumann BC, Noa K, Wileyto EP, Bekelman JE, Deville C, Vapiwala N, Kirk M, Both S, Dolney D, Kassaee A, Christodouleas JP.

Med Dosim. 2015 Winter;40(4):372-7. doi: 10.1016/j.meddos.2015.06.001. Epub 2015 Aug 29.

PMID:
26323390
31.

Effective palliation of intractable bleeding from Noonan syndrome-associated lymphatic malformations by radiotherapy.

Baumann BC, MacArthur KM, Rosenbach M, Miller JC, Ben-Josef E.

Acta Derm Venereol. 2015 Nov;95(8):1009-10. doi: 10.2340/00015555-2109. No abstract available.

32.

Occult pelvic lymph node involvement in bladder cancer: implications for definitive radiation.

Goldsmith B, Baumann BC, He J, Tucker K, Bekelman J, Deville C, Vapiwala N, Vaughn D, Keefe SM, Guzzo T, Malkowicz SB, Christodouleas JP.

Int J Radiat Oncol Biol Phys. 2014 Mar 1;88(3):603-10. doi: 10.1016/j.ijrobp.2013.11.211. Epub 2014 Jan 7.

PMID:
24411628
33.

Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710.

Christodouleas JP, Baumann BC, He J, Hwang WT, Tucker KN, Bekelman JE, Tangen CM, Lerner SP, Guzzo TJ, Malkowicz SB, Herr H.

Cancer. 2014 Apr 15;120(8):1272-80. doi: 10.1002/cncr.28544. Epub 2014 Jan 3. Erratum in: Cancer. 2015 Jan 1;121(1):162. Herr, Harry [added].

34.

Salmon and human thrombin differentially regulate radicular pain, glial-induced inflammation and spinal neuronal excitability through protease-activated receptor-1.

Smith JR, Syre PP, Oake SA, Nicholson KJ, Weisshaar CL, Cruz K, Bucki R, Baumann BC, Janmey PA, Winkelstein BA.

PLoS One. 2013 Nov 20;8(11):e80006. doi: 10.1371/journal.pone.0080006. eCollection 2013.

35.

Selective targeting of brain tumors with gold nanoparticle-induced radiosensitization.

Joh DY, Sun L, Stangl M, Al Zaki A, Murty S, Santoiemma PP, Davis JJ, Baumann BC, Alonso-Basanta M, Bhang D, Kao GD, Tsourkas A, Dorsey JF.

PLoS One. 2013 Apr 30;8(4):e62425. doi: 10.1371/journal.pone.0062425. Print 2013.

36.

Enhancing the efficacy of drug-loaded nanocarriers against brain tumors by targeted radiation therapy.

Baumann BC, Kao GD, Mahmud A, Harada T, Swift J, Chapman C, Xu X, Discher DE, Dorsey JF.

Oncotarget. 2013 Jan;4(1):64-79.

37.

Stereotactic intracranial implantation and in vivo bioluminescent imaging of tumor xenografts in a mouse model system of glioblastoma multiforme.

Baumann BC, Dorsey JF, Benci JL, Joh DY, Kao GD.

J Vis Exp. 2012 Sep 25;(67). pii: 4089. doi: 10.3791/4089.

38.

An integrated method for reproducible and accurate image-guided stereotactic cranial irradiation of brain tumors using the small animal radiation research platform.

Baumann BC, Benci JL, Santoiemma PP, Chandrasekaran S, Hollander AB, Kao GD, Dorsey JF.

Transl Oncol. 2012 Aug;5(4):230-7. Epub 2012 Aug 1.

39.

Bladder cancer patterns of pelvic failure: implications for adjuvant radiation therapy.

Baumann BC, Guzzo TJ, He J, Vaughn DJ, Keefe SM, Vapiwala N, Deville C, Bekelman JE, Tucker K, Hwang WT, Malkowicz SB, Christodouleas JP.

Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):363-9. doi: 10.1016/j.ijrobp.2012.03.061. Epub 2012 May 30.

PMID:
22658217
40.

A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy.

Baumann BC, Guzzo TJ, He J, Keefe SM, Tucker K, Bekelman JE, Hwang WT, Vaughn DJ, Malkowicz SB, Christodouleas JP.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):81-8. doi: 10.1016/j.ijrobp.2012.03.007. Epub 2012 Apr 28.

PMID:
22543204
41.

Astrocyte-elevated gene-1 (AEG-1): Glioblastoma's helping hand during times of hypoxia and glucose deprivation?

Baumann BC, Dorsey JF.

Cancer Biol Ther. 2011 Jan 1;11(1):40-2. Epub 2011 Jan 1. No abstract available.

PMID:
21150314
42.

Reduced DNAM-1 expression on bone marrow NK cells associated with impaired killing of CD34+ blasts in myelodysplastic syndrome.

Carlsten M, Baumann BC, Simonsson M, Jädersten M, Forsblom AM, Hammarstedt C, Bryceson YT, Ljunggren HG, Hellström-Lindberg E, Malmberg KJ.

Leukemia. 2010 Sep;24(9):1607-16. doi: 10.1038/leu.2010.149. Epub 2010 Jul 8.

PMID:
20613786
43.

HLA-Cw4 expression on porcine endothelial cells reduces cytotoxicity and adhesion mediated by CD158a+ human NK cells.

Forte P, Baumann BC, Schneider MK, Seebach JD.

Xenotransplantation. 2009 Jan-Feb;16(1):19-26. doi: 10.1111/j.1399-3089.2009.00510.x.

PMID:
19243557
44.

Estimation of the size of the alloreactive NK cell repertoire: studies in individuals homozygous for the group A KIR haplotype.

Fauriat C, Andersson S, Björklund AT, Carlsten M, Schaffer M, Björkström NK, Baumann BC, Michaëlsson J, Ljunggren HG, Malmberg KJ.

J Immunol. 2008 Nov 1;181(9):6010-9.

45.

NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy.

Malmberg KJ, Bryceson YT, Carlsten M, Andersson S, Björklund A, Björkström NK, Baumann BC, Fauriat C, Alici E, Dilber MS, Ljunggren HG.

Cancer Immunol Immunother. 2008 Oct;57(10):1541-52. doi: 10.1007/s00262-008-0492-7. Epub 2008 Mar 4. Review.

PMID:
18317755
46.

Characterization of natural human anti-non-gal antibodies and their effect on activation of porcine gal-deficient endothelial cells.

Saethre M, Baumann BC, Fung M, Seebach JD, Mollnes TE.

Transplantation. 2007 Jul 27;84(2):244-50.

PMID:
17667817
47.

Transgenic expression of HLA-E single chain trimer protects porcine endothelial cells against human natural killer cell-mediated cytotoxicity.

Lilienfeld BG, Crew MD, Forte P, Baumann BC, Seebach JD.

Xenotransplantation. 2007 Mar;14(2):126-34.

PMID:
17381687
48.

DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.

Carlsten M, Björkström NK, Norell H, Bryceson Y, van Hall T, Baumann BC, Hanson M, Schedvins K, Kiessling R, Ljunggren HG, Malmberg KJ.

Cancer Res. 2007 Feb 1;67(3):1317-25.

49.

Reactivity of human natural antibodies to endothelial cells from Galalpha(1,3)Gal-deficient pigs.

Baumann BC, Stussi G, Huggel K, Rieben R, Seebach JD.

Transplantation. 2007 Jan 27;83(2):193-201.

PMID:
17264816
50.

Human NK cytotoxicity against porcine cells is triggered by NKp44 and NKG2D.

Forte P, Lilienfeld BG, Baumann BC, Seebach JD.

J Immunol. 2005 Oct 15;175(8):5463-70.

Supplemental Content

Loading ...
Support Center